Healios KK (JP:4593) has released an update.
Healios KK, in collaboration with Sumitomo Pharma, has initiated a phase 1/2 clinical study for treating retinal pigment epithelium (RPE) tears using allogeneic iPS cell-derived RPE cells, with the first patient enrolled at Kyushu University Hospital. The study aims to commercialize the treatment and establish its efficacy and safety to benefit patients swiftly. As of now, the development has no confirmed impact on Healios KK’s financial performance for the fiscal year.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.
